logo-loader
viewSyngenta AG (ADR)

Syngenta agrees to $105 mln settlement for herbicide litigation

corn350_4fbf8a72acdbe.jpg

Switzerland-based Syngenta (NYSE:SYT) announced Friday a $105 million settlement in the United States for a case surrounding its weed killer atrazine, which was said to have entered several community water systems.

The case was brought upon by the community water systems who wanted Syngenta to pay for the chemical to be filtered from their supplies.

Syngenta, an agrochemicals crop protection and seed company, settled the litigation in order to end business uncertainty, and avoid further expenses of protracted legal proceedings, it said in a statement.

Under the terms of the agreement, Syngenta denied liability, and the plaintiffs acknowledged that the company was not aware of any new scientific studies relating to atrazine.

The total cost of settling was $105 million, which will be charged to Syngenta's income statement in 2012. This fee is partly covered by provisions, the company said.

The earnings impact will be roughly 50 cents per share.

The company is waiting to have the settlement agreement with plaintiffs approved by the United States District Court for the Southern District of Illinois.

Syngenta will continue to market the herbicide atrazine as part of its corn herbicide portfolio, since it allows growers in the United States to achieve optimal weed control.

The company recently reported that the herbicide is used in over 60 countries and meets strict safety regulations.

Syngenta is located across 90 countries, and is focused on increasing crop productivity, protecting the environment, and improving health and quality of life.

Shares were down more than 1 per cent in early trading Friday morning in New York, at $63.3.

Quick facts: Syngenta AG (ADR)

Price: - -

NYSE:SYT
Market: NYSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

16 hours, 5 minutes ago

2 min read